November 15, 2019

New Novartis Medicine Adakveo® (crizanlizumab) Approved by FDA to Reduce Frequency of Pain Crises in Individuals Living with Sickle Cell Disease

Therapy developed by MPM portfolio company Selexys, acquired by Novartis in 2016